Gilead signs immuno-oncology deal with Tango

02-11-2018

Gilead signs immuno-oncology deal with Tango

wildpixel / iStockphoto.com

California-based Gilead Sciences has signed a collaboration agreement with Tango Therapeutics to discover and develop a pipeline of immuno-oncology treatments for cancer patients.


Gilead Sciences, Tango Therapeutics, immuno-oncology, collaboration, cancer, oncology, therapeutics

LSIPR